PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. Expand Their Drug Discovery Partnership
6/17/2013 9:23:58 AM
More...
|
Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients With Schizophrenia Compared to Seroquel XR® (quetiapine XR)
5/21/2013 10:51:38 AM
More...
|
Sunovion Pharmaceuticals Inc. Presents Results From a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution
5/20/2013 10:23:33 AM
More...
|
Sunovion Pharmaceuticals Inc. to Present Three Posters on Results of One-year Large Simple Safety Study for BROVANA® (arformoterol tartrate) Inhalation Solution at 2013 American Thoracic Society International Conference
5/16/2013 10:05:52 AM
More...
|
Sunovion Pharmaceuticals Inc. Selects BioPharm Systems, Inc. 's Siebel Clinical Trial Management System Accelerator to Facilitate Fully Outsourced Clinical Trial Management Model
3/29/2013 9:53:28 AM
More...
|
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA® (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults With Epilepsy
2/27/2013 11:02:15 AM
More...
|
Sunovion Pharmaceuticals Inc. to Close Down Operations Along With 32 Local Jobs
12/6/2012 7:40:41 AM
More...
|
Sunovion Pharmaceuticals Inc. Presents New Clinical Safety Data From the Pediatric Development Program for ZETONNA® (ciclesonide) Nasal Aerosol at American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting
11/12/2012 9:55:49 AM
More...
|
PsychoGenics Inc. Achieves Substantial Milestone in Its Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc.
11/5/2012 9:49:18 AM
More...
|
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of 2 sNDAs for Latuda® as Monotherapy and Adjunctive Therapy in Adult Patients With Depressive Episodes Associated with Bipolar I Disorder
10/30/2012 7:07:13 AM
More...
|
|